annual cash & cash equivalents:
$298.26M-$91.22M(-23.42%)Summary
- As of today (September 11, 2025), CRSP annual cash & cash equivalents is $298.26 million, with the most recent change of -$91.22 million (-23.42%) on December 31, 2024.
- During the last 3 years, CRSP annual cash & cash equivalents has fallen by -$624.77 million (-67.69%).
- CRSP annual cash & cash equivalents is now -74.48% below its all-time high of $1.17 billion, reached on December 31, 2020.
Performance
CRSP Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.72B-$134.05M(-7.21%)Summary
- As of today (September 11, 2025), CRSP quarterly cash & cash equivalents is $1.72 billion, with the most recent change of -$134.05 million (-7.21%) on June 30, 2025.
- Over the past year, CRSP quarterly cash & cash equivalents has dropped by -$276.87 million (-13.83%).
- CRSP quarterly cash & cash equivalents is now -33.39% below its all-time high of $2.59 billion, reached on June 30, 2021.
Performance
CRSP quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CRSP Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.4% | -13.8% |
| 3 y3 years | -67.7% | -16.5% |
| 5 y5 years | -68.4% | +82.5% |
CRSP Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -67.7% | +40.8% | -18.2% | +1.8% |
| 5 y | 5-year | -74.5% | +40.8% | -33.4% | +82.5% |
| alltime | all time | -74.5% | >+9999.0% | -33.4% | +1005.9% |
CRSP Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $1.72B(-7.2%) |
| Mar 2025 | - | $1.86B(-2.4%) |
| Dec 2024 | $298.26M(-23.4%) | $1.90B(-1.6%) |
| Sep 2024 | - | $1.94B(-3.3%) |
| Jun 2024 | - | $2.00B(-5.1%) |
| Mar 2024 | - | $2.11B(+24.5%) |
| Dec 2023 | $389.48M(+83.8%) | $1.69B(-2.7%) |
| Sep 2023 | - | $1.74B(-1.6%) |
| Jun 2023 | - | $1.77B(-6.1%) |
| Mar 2023 | - | $1.88B(+3.7%) |
| Dec 2022 | $211.88M(-77.0%) | $1.82B(-4.3%) |
| Sep 2022 | - | $1.90B(-8.2%) |
| Jun 2022 | - | $2.07B(-7.0%) |
| Mar 2022 | - | $2.22B(-6.6%) |
| Dec 2021 | $923.03M(-21.0%) | $2.38B(-4.0%) |
| Sep 2021 | - | $2.48B(-4.3%) |
| Jun 2021 | - | $2.59B(+43.4%) |
| Mar 2021 | - | $1.81B(+6.9%) |
| Dec 2020 | $1.17B | $1.69B(+23.7%) |
| Sep 2020 | - | $1.37B(+44.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $945.07M(+6.2%) |
| Mar 2020 | - | $889.71M(-5.7%) |
| Dec 2019 | $943.77M(+106.7%) | $943.77M(+49.9%) |
| Sep 2019 | - | $629.72M(+47.2%) |
| Jun 2019 | - | $427.88M(-2.2%) |
| Mar 2019 | - | $437.55M(-4.2%) |
| Dec 2018 | $456.65M(+90.5%) | $456.65M(-6.3%) |
| Sep 2018 | - | $487.30M(+52.4%) |
| Jun 2018 | - | $319.74M(-6.4%) |
| Mar 2018 | - | $341.77M(+42.5%) |
| Dec 2017 | $239.76M(-24.0%) | $239.76M(-5.4%) |
| Sep 2017 | - | $253.52M(-6.9%) |
| Jun 2017 | - | $272.26M(-5.7%) |
| Mar 2017 | - | $288.87M(-8.4%) |
| Dec 2016 | $315.52M(+102.3%) | $315.52M(+38.0%) |
| Sep 2016 | - | $228.61M(-7.4%) |
| Jun 2016 | - | $246.85M(+23.1%) |
| Mar 2016 | - | $200.60M(+28.6%) |
| Dec 2015 | $155.96M(>+9900.0%) | $155.96M |
| Dec 2014 | $945.00K | - |
FAQ
- What is CRISPR Therapeutics AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly cash & cash equivalents year-on-year change?
What is CRISPR Therapeutics AG annual cash & cash equivalents?
The current annual cash & cash equivalents of CRSP is $298.26M
What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash & cash equivalents is $1.17B
What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
Over the past year, CRSP annual cash & cash equivalents has changed by -$91.22M (-23.42%)
What is CRISPR Therapeutics AG quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CRSP is $1.72B
What is the all time high quarterly cash & cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash & cash equivalents is $2.59B
What is CRISPR Therapeutics AG quarterly cash & cash equivalents year-on-year change?
Over the past year, CRSP quarterly cash & cash equivalents has changed by -$276.87M (-13.83%)